Integra LifeSciences
IART
281 hedge funds and large institutions have $2.34B invested in Integra LifeSciences in 2024 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 108 increasing their positions, 96 reducing their positions, and 40 closing their positions.
70% more call options, than puts
Call options by funds: $773K | Put options by funds: $454K
13% more repeat investments, than reductions
Existing positions increased: 108 | Existing positions reduced: 96
5% less first-time investments, than exits
New positions opened: 38 | Existing positions closed: 40
1% less funds holding
Funds holding: 284 → 281 (-3)
7.92% less ownership
Funds ownership: 92.36% → 84.44% (-7.9%)
26% less capital invested
Capital invested by funds: $3.14B → $2.34B (-$803M)
100% less funds holding in top 10
Funds holding in top 10: 4 → 0 (-4)
Top Buyers
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$64.9M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
+$22.5M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$19.8M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$14.1M |
| 5 |
DM
Deerfield Management
New York
|
+$13.8M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$225M |
| 2 |
ClearBridge Investments
New York
|
-$108M |
| 3 |
MAP
Madison Avenue Partners
New York
|
-$45.4M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$20.7M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$16M |
IART Hedge Fund Activity: Q1 2024 in Review
281 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q1 2024, worth a combined $2.34B — down 26% from $3.14B a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of IART and 38 opened new positions — a net loss of 2 holders — while 96 trimmed existing stakes and 108 added.
The largest buyer was Capital Research Global Investors, adding an estimated $64.9M. The largest seller was Morgan Stanley, cutting an estimated $225M.
- 281 institutional investors held Integra LifeSciences (IART) as of Q1 2024, down from 284 in Q4 2023.
- Funds reported $2.34B of Integra LifeSciences stock for Q1 2024, down 26% quarter-over-quarter.
- 38 funds opened new Integra LifeSciences positions in Q1 2024 and 40 closed out, a net change of -2 holders.
- The largest Integra LifeSciences buyer in Q1 2024 was Capital Research Global Investors, an estimated $64.9M added.
- The largest Integra LifeSciences seller in Q1 2024 was Morgan Stanley, an estimated $225M sold.
Based on aggregated 13F filings for Q1 2024.